NeoGenomics (NeoGenomics) Debt-to-Asset : 0.37 (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Debt-to-Asset?

NeoGenomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.5 Mil. NeoGenomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $603.7 Mil. NeoGenomics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $1,640.3 Mil. NeoGenomics's debt to asset for the quarter that ended in Mar. 2024 was 0.37.

NeoGenomics Debt-to-Asset Historical Data

The historical data trend for NeoGenomics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Debt-to-Asset Chart

NeoGenomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.19

0.22

0.33

0.35

0.36

NeoGenomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.36	0.36	0.36	0.36	0.37

Competitive Comparison of NeoGenomics's Debt-to-Asset

For the Diagnostics & Research subindustry, NeoGenomics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeoGenomics's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Debt-to-Asset falls into.

NeoGenomics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NeoGenomics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.61	+	606.069)	/	1681.229
	=	0.36

NeoGenomics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.487	+	603.696)	/	1640.339
	=	0.37

NeoGenomics (NAS:NEO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

NeoGenomics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoGenomics (NeoGenomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Debt-to-Asset

Comparable Companies

TWST MYGN GH VCYT NEOG LAB OPK FLGT CSTL CDNA TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

NG9:Germany

Address

9490 NeoGenomics Way, Fort Myers, FL, USA, 33912

Website

https://www.neogenomics.com

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

Executives

Alicia C Olivo	officer: General Counsel	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook	director	C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel	director	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn	director	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan	officer: Chief Accounting Officer	HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman	officer: Chief Financial Officer	103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris	officer: President, Enterprise Ops	4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone	officer: President, Clinical Services	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez	director	12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith	officer: Chief Executive Officer	125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni	officer: President of Lab Operations	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri	officer: President and CCO, Inivata	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar	officer: President, Clinical Services	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello	officer: VP, Investor Relations	12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie	officer: Principal Accounting Officer	12780 WESTLINKS DRIVE, FORT MYERS FL 33913